bpc 157 regulatory status fda 2025 Peptide Reclassification 2026: What It Means for Providers FDA's Overreach on Compounded Peptides

The peptides compensate for age-related decline in natural healing factors, helping older adults recover from injuries at rates closer to younger individuals

Key finding: AOD-9604 failed to produce statistically significant weight loss compared to placebo in a clinical trial

A few clinic-based reports and testimonials suggest subjective improvement in energy or appetite control, but those are susceptible to placebo effects, co-interventions (sleep, hydration, counseling), and selection bias

For chronic GI conditions including irritable bowel syndrome, inflammatory bowel disease, gastritis, and peptic ulcers, the peptide may offer unique benefits